US FDA

OOS Investigations - FDA Requirements

The Phase I and Phase II investigation framework FDA expects for every out-of-specification result.

What this course covers

This course covers FDA's Phase I laboratory and Phase II manufacturing investigation framework for out-of-specification results, and the documentation standard inspectors expect an OOS investigation file to meet. For a deeper walk-through of the enforcement pattern behind 21 CFR 211.192, the number one FDA 483 citation four years running, see the full breakdown on the GMPify blog.

Who this course is for

Laboratory and QA staff who conduct or review OOS investigations
Site leadership overseeing investigation quality before batch disposition decisions

What you'll learn

The Phase I laboratory and Phase II manufacturing investigation framework under FDA's OOS guidance
What distinguishes a defensible OOS investigation from one that will not survive inspection
The documentation standard inspectors expect an OOS investigation file to meet

Why it matters

21 CFR 211.192 has been the most or second most cited provision in FDA drug 483 observations for multiple consecutive years, and OOS investigations sit at the center of that citation pattern. A shallow root cause, most often 'human error' with no further explanation, is the single most common reason an OOS investigation fails at inspection.

Included in the full GMPify subscription

Completion certificate, PDF slide download, and access to the complete GMP course library from day one.

Start this course →